3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer
Chronic inflammation is closely linked to cancer. The risk of damage by colorectal cancer (CRC) may increase due to autoimmune disease and cryptogenic inflammation. Therefore, genetic factors implicated in the chronic irritation in inflammatory bowel disease such as NOD2/CARD15 may predispose to CRC...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2014-05, Vol.31 (5), p.954, Article 954 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 954 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 31 |
| creator | Omrane, Inés Mezlini, Amel Baroudi, Olfa Stambouli, Nejla Bougatef, Karim Ayari, Hager Medimegh, Imen Bouzaienne, Hassen Uhrhammer, Nancy Bignon, Yves-Jean Benammar-Elgaaied, Amel Marrakchi, Raja |
| description | Chronic inflammation is closely linked to cancer. The risk of damage by colorectal cancer (CRC) may increase due to autoimmune disease and cryptogenic inflammation. Therefore, genetic factors implicated in the chronic irritation in inflammatory bowel disease such as NOD2/CARD15 may predispose to CRC. In this report, we shed the light on the possible contribution of the NOD2 3020insC variant to CRC risk in a series of 246 Tunisian subjects including 101 patients with CRC and 145 healthy controls. NOD2/CARD15 polymorphism was genotyped by sizing fluorescently labeled PCR products and automated sequencers. We analyzed the association between the molecular features at this gene in relation to tumor and patient characteristics and treatments. Through this qualitative analysis, we found that CRC patients with mutant allele of NOD2/CARD15 were suffering from Crohn’s disease (CD) with canonic presentation. We also observed a positive association between 3020insC polymorphism and surgery and chemotherapy. We suppose that around 3 % of colorectal cases which happen at an age older than 50 years are associated with the canonic form of CD along with the 3020insC mutation and that these patients are in need for chemotherapy. |
| doi_str_mv | 10.1007/s12032-014-0954-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1520095202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3290282101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-ba936f9efdda19fa737f5d1d84a3ed598d353e80452bb8b829dd972662ba61313</originalsourceid><addsrcrecordid>eNp1kF9LwzAUxYMobk4_gC9S8LnuJmna5nF0_oPhRBR8C2mTuo62qUmHbJ_ejE7xxad74Z5zLueH0CWGGwyQTB0mQEkIOAqBsyjcHaExZoyHmOL3Y79TloTAYhihM-fWAAQzwk_RiEQJ5kDTMXqmQKBqXRY8Ledkms1e5pgFnam3jbHdqnJNIJ0zRSV7rYKvql8FvdWyb3TbB6YMClMbq4te1kEh20Lbc3RSytrpi8OcoLe729fsIVws7x-z2SIsooj0YS45jUuuS6Uk5qVMaFIyhVUaSaoV46mijOoUIkbyPM1TwpXiCYljksvY16MTdD3kdtZ8brTrxdpsbOtfCl8SPA8CxKvwoCqscc7qUnS2aqTdCgxiz1AMDIVnKPYMxc57rg7Jm7zR6tfxA80LyCBw_tR-aPvn9b-p35x_e0U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1520095202</pqid></control><display><type>article</type><title>3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Omrane, Inés ; Mezlini, Amel ; Baroudi, Olfa ; Stambouli, Nejla ; Bougatef, Karim ; Ayari, Hager ; Medimegh, Imen ; Bouzaienne, Hassen ; Uhrhammer, Nancy ; Bignon, Yves-Jean ; Benammar-Elgaaied, Amel ; Marrakchi, Raja</creator><creatorcontrib>Omrane, Inés ; Mezlini, Amel ; Baroudi, Olfa ; Stambouli, Nejla ; Bougatef, Karim ; Ayari, Hager ; Medimegh, Imen ; Bouzaienne, Hassen ; Uhrhammer, Nancy ; Bignon, Yves-Jean ; Benammar-Elgaaied, Amel ; Marrakchi, Raja</creatorcontrib><description>Chronic inflammation is closely linked to cancer. The risk of damage by colorectal cancer (CRC) may increase due to autoimmune disease and cryptogenic inflammation. Therefore, genetic factors implicated in the chronic irritation in inflammatory bowel disease such as NOD2/CARD15 may predispose to CRC. In this report, we shed the light on the possible contribution of the NOD2 3020insC variant to CRC risk in a series of 246 Tunisian subjects including 101 patients with CRC and 145 healthy controls. NOD2/CARD15 polymorphism was genotyped by sizing fluorescently labeled PCR products and automated sequencers. We analyzed the association between the molecular features at this gene in relation to tumor and patient characteristics and treatments. Through this qualitative analysis, we found that CRC patients with mutant allele of NOD2/CARD15 were suffering from Crohn’s disease (CD) with canonic presentation. We also observed a positive association between 3020insC polymorphism and surgery and chemotherapy. We suppose that around 3 % of colorectal cases which happen at an age older than 50 years are associated with the canonic form of CD along with the 3020insC mutation and that these patients are in need for chemotherapy.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-014-0954-z</identifier><identifier>PMID: 24719038</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biomarkers, Tumor - genetics ; Case-Control Studies ; Colorectal cancer ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - therapy ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Genetic Predisposition to Disease ; Genotype ; Hematology ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutagenesis, Insertional - genetics ; Neoplasm Metastasis ; Neoplasm Staging ; Nod2 Signaling Adaptor Protein - genetics ; Oncology ; Original Paper ; Pathology ; Phenotype ; Polymorphism, Genetic - genetics ; Prognosis ; Tunisia</subject><ispartof>Medical oncology (Northwood, London, England), 2014-05, Vol.31 (5), p.954, Article 954</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-ba936f9efdda19fa737f5d1d84a3ed598d353e80452bb8b829dd972662ba61313</citedby><cites>FETCH-LOGICAL-c442t-ba936f9efdda19fa737f5d1d84a3ed598d353e80452bb8b829dd972662ba61313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-014-0954-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-014-0954-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24719038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Omrane, Inés</creatorcontrib><creatorcontrib>Mezlini, Amel</creatorcontrib><creatorcontrib>Baroudi, Olfa</creatorcontrib><creatorcontrib>Stambouli, Nejla</creatorcontrib><creatorcontrib>Bougatef, Karim</creatorcontrib><creatorcontrib>Ayari, Hager</creatorcontrib><creatorcontrib>Medimegh, Imen</creatorcontrib><creatorcontrib>Bouzaienne, Hassen</creatorcontrib><creatorcontrib>Uhrhammer, Nancy</creatorcontrib><creatorcontrib>Bignon, Yves-Jean</creatorcontrib><creatorcontrib>Benammar-Elgaaied, Amel</creatorcontrib><creatorcontrib>Marrakchi, Raja</creatorcontrib><title>3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Chronic inflammation is closely linked to cancer. The risk of damage by colorectal cancer (CRC) may increase due to autoimmune disease and cryptogenic inflammation. Therefore, genetic factors implicated in the chronic irritation in inflammatory bowel disease such as NOD2/CARD15 may predispose to CRC. In this report, we shed the light on the possible contribution of the NOD2 3020insC variant to CRC risk in a series of 246 Tunisian subjects including 101 patients with CRC and 145 healthy controls. NOD2/CARD15 polymorphism was genotyped by sizing fluorescently labeled PCR products and automated sequencers. We analyzed the association between the molecular features at this gene in relation to tumor and patient characteristics and treatments. Through this qualitative analysis, we found that CRC patients with mutant allele of NOD2/CARD15 were suffering from Crohn’s disease (CD) with canonic presentation. We also observed a positive association between 3020insC polymorphism and surgery and chemotherapy. We suppose that around 3 % of colorectal cases which happen at an age older than 50 years are associated with the canonic form of CD along with the 3020insC mutation and that these patients are in need for chemotherapy.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Case-Control Studies</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutagenesis, Insertional - genetics</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Nod2 Signaling Adaptor Protein - genetics</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Phenotype</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Prognosis</subject><subject>Tunisia</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kF9LwzAUxYMobk4_gC9S8LnuJmna5nF0_oPhRBR8C2mTuo62qUmHbJ_ejE7xxad74Z5zLueH0CWGGwyQTB0mQEkIOAqBsyjcHaExZoyHmOL3Y79TloTAYhihM-fWAAQzwk_RiEQJ5kDTMXqmQKBqXRY8Ledkms1e5pgFnam3jbHdqnJNIJ0zRSV7rYKvql8FvdWyb3TbB6YMClMbq4te1kEh20Lbc3RSytrpi8OcoLe729fsIVws7x-z2SIsooj0YS45jUuuS6Uk5qVMaFIyhVUaSaoV46mijOoUIkbyPM1TwpXiCYljksvY16MTdD3kdtZ8brTrxdpsbOtfCl8SPA8CxKvwoCqscc7qUnS2aqTdCgxiz1AMDIVnKPYMxc57rg7Jm7zR6tfxA80LyCBw_tR-aPvn9b-p35x_e0U</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Omrane, Inés</creator><creator>Mezlini, Amel</creator><creator>Baroudi, Olfa</creator><creator>Stambouli, Nejla</creator><creator>Bougatef, Karim</creator><creator>Ayari, Hager</creator><creator>Medimegh, Imen</creator><creator>Bouzaienne, Hassen</creator><creator>Uhrhammer, Nancy</creator><creator>Bignon, Yves-Jean</creator><creator>Benammar-Elgaaied, Amel</creator><creator>Marrakchi, Raja</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140501</creationdate><title>3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer</title><author>Omrane, Inés ; Mezlini, Amel ; Baroudi, Olfa ; Stambouli, Nejla ; Bougatef, Karim ; Ayari, Hager ; Medimegh, Imen ; Bouzaienne, Hassen ; Uhrhammer, Nancy ; Bignon, Yves-Jean ; Benammar-Elgaaied, Amel ; Marrakchi, Raja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-ba936f9efdda19fa737f5d1d84a3ed598d353e80452bb8b829dd972662ba61313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Case-Control Studies</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutagenesis, Insertional - genetics</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Nod2 Signaling Adaptor Protein - genetics</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Phenotype</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Prognosis</topic><topic>Tunisia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Omrane, Inés</creatorcontrib><creatorcontrib>Mezlini, Amel</creatorcontrib><creatorcontrib>Baroudi, Olfa</creatorcontrib><creatorcontrib>Stambouli, Nejla</creatorcontrib><creatorcontrib>Bougatef, Karim</creatorcontrib><creatorcontrib>Ayari, Hager</creatorcontrib><creatorcontrib>Medimegh, Imen</creatorcontrib><creatorcontrib>Bouzaienne, Hassen</creatorcontrib><creatorcontrib>Uhrhammer, Nancy</creatorcontrib><creatorcontrib>Bignon, Yves-Jean</creatorcontrib><creatorcontrib>Benammar-Elgaaied, Amel</creatorcontrib><creatorcontrib>Marrakchi, Raja</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Omrane, Inés</au><au>Mezlini, Amel</au><au>Baroudi, Olfa</au><au>Stambouli, Nejla</au><au>Bougatef, Karim</au><au>Ayari, Hager</au><au>Medimegh, Imen</au><au>Bouzaienne, Hassen</au><au>Uhrhammer, Nancy</au><au>Bignon, Yves-Jean</au><au>Benammar-Elgaaied, Amel</au><au>Marrakchi, Raja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>31</volume><issue>5</issue><spage>954</spage><pages>954-</pages><artnum>954</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Chronic inflammation is closely linked to cancer. The risk of damage by colorectal cancer (CRC) may increase due to autoimmune disease and cryptogenic inflammation. Therefore, genetic factors implicated in the chronic irritation in inflammatory bowel disease such as NOD2/CARD15 may predispose to CRC. In this report, we shed the light on the possible contribution of the NOD2 3020insC variant to CRC risk in a series of 246 Tunisian subjects including 101 patients with CRC and 145 healthy controls. NOD2/CARD15 polymorphism was genotyped by sizing fluorescently labeled PCR products and automated sequencers. We analyzed the association between the molecular features at this gene in relation to tumor and patient characteristics and treatments. Through this qualitative analysis, we found that CRC patients with mutant allele of NOD2/CARD15 were suffering from Crohn’s disease (CD) with canonic presentation. We also observed a positive association between 3020insC polymorphism and surgery and chemotherapy. We suppose that around 3 % of colorectal cases which happen at an age older than 50 years are associated with the canonic form of CD along with the 3020insC mutation and that these patients are in need for chemotherapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24719038</pmid><doi>10.1007/s12032-014-0954-z</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2014-05, Vol.31 (5), p.954, Article 954 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_1520095202 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biomarkers, Tumor - genetics Case-Control Studies Colorectal cancer Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Combined Modality Therapy Female Follow-Up Studies Genetic Predisposition to Disease Genotype Hematology Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Mutagenesis, Insertional - genetics Neoplasm Metastasis Neoplasm Staging Nod2 Signaling Adaptor Protein - genetics Oncology Original Paper Pathology Phenotype Polymorphism, Genetic - genetics Prognosis Tunisia |
| title | 3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T10%3A34%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=3020insC%20NOD2/CARD15%20polymorphism%20associated%20with%20treatment%20of%20colorectal%20cancer&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Omrane,%20In%C3%A9s&rft.date=2014-05-01&rft.volume=31&rft.issue=5&rft.spage=954&rft.pages=954-&rft.artnum=954&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-014-0954-z&rft_dat=%3Cproquest_cross%3E3290282101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1520095202&rft_id=info:pmid/24719038&rfr_iscdi=true |